New data shows SOF-SKN active ingredient efficacy
| Stock | Noxopharm Ltd (NOX.ASX) |
|---|---|
| Release Time | 1 May 2026, 9:08 a.m. |
| Price Sensitive | Yes |
New data shows SOF-SKN active ingredient efficacy
- New research describes Sofra™ translation into drug candidates
- Efficacy shown in vitro on blood from patients with systemic lupus
- Additional potential demonstrated in samples from rheumatoid arthritis patients
Noxopharm Limited (ASX:NOX) has announced the release of new data showing the potential of its Sofra™ technology platform in samples from patients with autoimmune disease. The data, posted as a bioRxiv preprint by Professor Michael Gantier of Hudson Institute of Medical Research, Noxopharm's exclusive strategic partner, provides further insights and data demonstrating how the findings of a recent Nature Immunology paper are being translated into the creation of new therapeutics. The results show that SOF-16, the active ingredient in the company's SOF-SKN™ cutaneous lupus drug candidate, has potent anti-inflammatory activity in two in vitro studies, involving blood and joint fluid samples from patients with systemic lupus erythematosus (SLE) and rheumatoid arthritis, respectively. In the SLE study, the blood of two SLE patients carrying a genetic mutation that causes hypersensitivity of Toll-like receptor 7 (TLR7) - a key target of Noxopharm's drug - was stimulated in vitro. The blood from these SLE patients showed higher levels of TLR7-driven inflammation compared to blood from healthy donors, and treatment with SOF-16 successfully blocked this inflammation. In the rheumatoid arthritis study, synovial fluid collected from the joints of rheumatoid arthritis patients triggered a TLR7-mediated inflammatory response that was significantly reduced by treatment with SOF-16. Noxopharm CEO Dr Olivier Laczka said the results bolster the data package the company is preparing for future regulatory submissions while providing further evidence of SOF-SKN's potential beyond topical applications for cutaneous lupus erythematosus.
The Sofra™ technology, which includes several other assets beyond SOF-16, could also be further utilised for rheumatoid arthritis, diabetes, and other diseases linked to immune system dysregulation.